ResMed stock (US7611521078): sleep apnea specialist under investor scrutiny after latest quarterly results

ResMed reported solid quarterly growth in its core sleep apnea and respiratory care business, but investors are weighing margin trends, competition and GLP-1 weight?loss drugs. What the latest numbers mean for the stock and where the business stands now.

ResMed stock remains in focus after the sleep apnea and respiratory care specialist recently reported another quarter of rising revenue and earnings, while investors continue to weigh the impact of new weight?loss drugs and changing market dynamics on long?term growth.

In its fiscal third quarter 2025, which ended March 31, 2025, ResMed reported higher revenue and adjusted earnings per share year over year, supported by strong demand for sleep apnea devices, masks and cloud?based software, according to ResMed investor update as of 04/24/2025.

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Medical technology / sleep and respiratory care
• Headquarters/country: San Diego, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Sleep apnea devices, masks, ventilation and SaaS for out?of?hospital care
• Home exchange/listing venue: NYSE (ticker: RMD)
• Trading currency: USD

ResMed Inc.: core business model

ResMed Inc. focuses on medical devices and digital solutions for sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic respiratory conditions. The company generates most of its revenue from systems that diagnose and treat obstructive sleep apnea, such as continuous positive airway pressure (CPAP) machines and related masks. In addition, it develops cloud?connected devices that transmit data to healthcare providers and patients.

The business model combines hardware, consumables and software. CPAP and bilevel devices are typically sold to durable medical equipment providers (DMEs) and clinics, which then supply patients under reimbursement schemes. Masks and accessories form a recurring revenue stream because they require regular replacement. The software portfolio, including digital platforms for homecare and out?of?hospital providers, adds another recurring and often higher?margin component, complemented by data analytics and workflow tools.

ResMed’s strategy emphasizes long?term relationships with healthcare providers and payors, supported by clinical data that show potential benefits of treating sleep apnea, such as improvements in quality of life and in some cases reduced cardiovascular risk. The company invests in research and development to improve device comfort, noise reduction and connectivity, aiming to increase patient adherence. It also expands its digital ecosystem to integrate patient monitoring, compliance tracking and telehealth features into one platform.

In recent years, ResMed has pursued targeted acquisitions to strengthen its software and out?of?hospital care footprint. These deals aim to extend the company’s reach beyond sleep apnea into broader chronic disease management and care coordination. The combination of devices, consumables and software allows ResMed to participate in multiple stages of the care pathway, from diagnosis through long?term therapy monitoring.

Another pillar of the business model is international expansion. ResMed generates a significant share of revenue outside the United States and continues to invest in distribution, localized products and regulatory approvals in Europe and Asia-Pacific. Currency movements, reimbursement changes and local competition can affect performance by region, but geographic diversification helps balance country?specific risks over time.

Main revenue and product drivers for ResMed Inc.

Sleep apnea therapy equipment remains the key revenue driver for ResMed. CPAP and bilevel devices, along with integrated humidifiers and accessories, form the backbone of the device portfolio. These systems are used to treat obstructive sleep apnea by keeping airways open during sleep. Sales are supported by rising diagnosis rates, aging populations and increasing awareness of the health risks of untreated sleep apnea among physicians and patients.

Masks and consumables provide an important recurring revenue component. Because masks, cushions and filters need periodic replacement, they generate ongoing demand once patients have started therapy. This recurring profile can smooth revenue fluctuations from device cycles and support margins. Product innovation focuses on comfort, fit and ease of use to maintain patient adherence and reduce therapy discontinuation.

ResMed also operates a software?as?a?service (SaaS) business targeting out?of?hospital care providers, including home health agencies, hospices and skilled nursing facilities. These platforms help manage workflows, billing, documentation and clinical data. Subscription and usage fees generate recurring revenue and can be less capital?intensive than hardware. The company sees this digital segment as a growth engine that complements its core device business by expanding its role across the continuum of care.

Ventilation and respiratory care products used in hospitals and home settings contribute another share of revenue. These include non?invasive ventilators and life?support systems for patients with chronic respiratory disease or neuromuscular disorders. Demand in this segment can be influenced by seasonal respiratory trends and broader public health events, which can lead to temporary spikes in usage and orders followed by normalization.

Geographically, the United States and Canada form ResMed’s largest market, supported by a well?developed reimbursement environment, established diagnostic infrastructure and a large base of DME partners. Europe and Asia-Pacific are meaningful contributors, with some markets still underpenetrated in terms of sleep apnea diagnosis and treatment. Over time, increased adoption in these regions could provide incremental growth potential, though regulatory and pricing environments vary considerably by country.

Pricing, reimbursement policies and competitive dynamics play a crucial role in shaping revenue. ResMed competes with other international medical technology companies in sleep and respiratory care, and tender processes, payer negotiations and technology shifts can influence average selling prices. The company seeks to differentiate through product performance, clinical evidence and integrated digital services rather than price alone.

Industry trends and competitive position

The global sleep apnea market is influenced by demographic factors, rising obesity rates and increased awareness of sleep?related breathing disorders. More primary care physicians and specialists screen for sleep apnea, and home sleep testing has become more common in many markets. These trends support demand for diagnosis and treatment solutions, including CPAP devices and masks, which directly benefits established players like ResMed.

At the same time, the launch and rapid uptake of GLP?1 weight?loss drugs have sparked debate about their long?term impact on sleep apnea therapy demand. Weight loss can improve or even resolve sleep apnea in some patients, potentially reducing the need for CPAP therapy in specific groups. However, clinical outcomes vary, and many patients with sleep apnea have additional anatomical or neuromuscular factors that may still require device?based treatment even with weight reduction.

ResMed’s competitive position has also been shaped by product recalls and supply challenges affecting some rivals in recent years. Disruptions in competitor offerings temporarily shifted demand toward alternative suppliers, giving ResMed an opportunity to win new patients and strengthen relationships with providers. As competitors address their quality and supply issues, the market may gradually normalize, and the durability of share gains remains an open question for investors.

Digital health and connectivity are another key trend. Cloud?connected devices, mobile apps and remote monitoring tools allow clinicians to track adherence, adjust settings and provide support without in?person visits. ResMed has invested heavily in connectivity and software platforms, which can improve patient engagement and create data?driven value propositions for payors and providers. Data security, privacy regulations and interoperability standards are important considerations in this area.

From a regulatory perspective, medical technology companies operate under strict quality and safety requirements, including approvals from authorities such as the U.S. Food and Drug Administration and European regulators. Compliance with evolving standards and post?market surveillance adds complexity and cost but also creates barriers to entry for new competitors. Companies with established quality systems and regulatory experience may be better positioned to navigate these requirements.

Why ResMed Inc. matters for US investors

For US investors, ResMed represents exposure to the intersection of medical technology, chronic disease management and digital health. The company is listed on the New York Stock Exchange under the ticker RMD and reports in U.S. dollars, making it accessible for many retail and institutional investors. Its core markets include the United States, where reimbursement frameworks and healthcare infrastructure support adoption of sleep and respiratory care solutions.

Sleep apnea and respiratory care remain significant healthcare challenges in the United States, with economic and clinical burdens spanning hospitalizations, cardiovascular comorbidities and reduced productivity. Companies that can improve diagnosis and long?term management of these conditions may benefit from secular demand tailwinds. ResMed’s focus on connected devices and software also aligns with broader trends toward remote monitoring and value?based care.

For portfolios that already include large diversified healthcare companies or pharmaceutical names, ResMed may offer a more focused exposure to a specific therapeutic area and device category. At the same time, investors need to consider factors such as reimbursement changes, competition, technology shifts and regulatory developments, which can all affect earnings trajectories and valuation multiples over time.

What type of investor might consider ResMed Inc. – and who should be cautious?

ResMed could be of interest to investors who follow the medical technology sector and are comfortable analyzing device makers with a mix of hardware, consumables and software revenue. The company has an established presence in sleep and respiratory care and participates in markets with long?term demographic growth drivers. Investors seeking exposure to digital health and remote monitoring themes may also track ResMed because of its connected device and SaaS offerings.

On the other hand, more cautious investors may focus on uncertainties linked to competitive dynamics, the potential impact of GLP?1 therapies on long?term CPAP demand, and the cyclical effects of inventory adjustments among equipment providers. Medical device companies can also face risks related to product quality, recalls and regulatory scrutiny, which may lead to volatility if issues arise. Currency movements and changes in reimbursement can add another layer of complexity for globally diversified businesses.

Short?term oriented traders may pay close attention to quarterly results, margin trends and management commentary on market share and pricing. Small deviations from expectations can lead to pronounced share price reactions in the medical technology sector. Long?term investors typically focus more on structural growth drivers, innovation pipeline and the company’s ability to maintain or expand its competitive position over several years.

Conclusion

ResMed sits at the crossroads of sleep medicine, respiratory care and digital health, with a business model that blends devices, recurring consumables and software. Recent quarterly results showed continued revenue and earnings growth, underlining persistent demand for sleep apnea therapy and connected solutions. At the same time, investors are monitoring how competitive dynamics, GLP?1 weight?loss drugs, reimbursement trends and regulatory requirements could shape future growth and margins. As with many specialized medical technology stocks, the balance between structural opportunities and sector?specific risks will likely remain central to how the market values ResMed over the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.